Neoplasm.News

Anti-TROP2 ADC × Breast × Clear all

2 Announcements

FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic triple-negative breast cancer

Drug: Datroway (datopotamab deruxtecan-dlnk) · Anti-TROP2 antibody-drug conjugate
Condition: Breast

FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer

Drug: Datroway (datopotamab deruxtecan-dlnk) · Anti-TROP2 antibody-drug conjugate
Condition: Breast